Review: Systemic therapy for advanced renal cell carcinoma

Therapeutic Advances in Medical Oncology

Volumn 1, Issue 1, 2009, Pages 15-27

  Larkin, James M G ^a   Kipps, Emma L s ^a   Powell, Ceri J ^a   Swanton, Charles ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b London Research Institute   (United Kingdom)

Author keywords

bevacizumab; everolimus; renal cell carcinoma; sorafenib; sunitinib; temsirolimus

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; ERLOTINIB; EVEROLIMUS; GEFITINIB; INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN; VOLOCIXIMAB;

ADJUVANT THERAPY; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HISTOLOGY; HUMAN; HYPERTENSION; IMMUNOTHERAPY; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PATHOLOGY; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; STOMATITIS; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77953435398     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009338430     Document Type: Review

References (86)

1. Atkins, M., Regan, M., McDermott, D., Mier, J., Stanbridge, E., Youmans, A. et al. (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11: 3714-3721.
2. Atzpodien, J., Schmitt, E., Gertenbach, U., Fornara, P., Heynemann, H., Maskow, A. et al. (2005) Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92: 843-846.
3. Bajetta, E., Ravaud, A., Bracarda, S., Négrier, S., Szczylik, C., Bellmunt Molins, J. et al. (2008) Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 May 20 suppl: abstr 5095.
4. Bracarda, S., Porta, C., Boni, C., Santoro, A., Artioli, F., Di Bartolomeo, C. et al. (2007) Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN in metastatic renal cell carcinoma (RAPSODY): GOIRC study 0681. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25: 5100.
5. Brugarolas, J. (2007) Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 356: 185-187.
6. Bukowski, R.M., Kabbinavar, F.F., Figlin, R.A., Flaherty, K., Srinivas, S., Vaishampayan, U. et al. (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25: 4536-4541.
7. Bukowski, R.M., Negrier, S. and Elson, P. (2004) Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 10: 6310S-6314S.
8. Choueiri, T.K., Plantade, A., Elson, P., Negrier, S., Ravaud, A., Oudard, S. et al. (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26: 127-131.
9. Clark, J.I., Atkins, M.B., Urba, W.J., Creech, S., Figlin, R.A., Dutcher, J.P. et al. (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21: 3133-3140.
10. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
11. Dawson, N.A., Guo, C., Zak, R., Dorsey, B., Smoot, J., Wong, J. et al. (2004) A phase II trial of gefitinib (Iressa, ZD 1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10: 7812-7819.
12. de Peralta-Venturina, M., Moch, H., Amin, M., Tamboli, P., Hailemariam, S., Mihatsch, M. et al. (2001) Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25: 275-284.
13. Drabkin, H.A., Figlin, R.A., Stadler, W.M., Hutson, T.E., Hajdenberg, J., Chu, L. et al. (2007) The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25: 5041.
14. Drucker, B., Bacik, J., Ginsberg, M., Marion, S., Russo, P., Mazumdar, M. et al. (2003) Phase II trial of ZD 1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 21: 341-345.
15. Duda, D.G., Batchelor, T.T., Willett, C.G. and Jain, R.K. (2007) VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 13: 223-230.
16. Dudek, A.Z., Zolnierek, J., Dham, A., Lindgren, B.R. and Szczylik, C. (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115: 61-67.
17. Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M. et al. (2007 a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
18. Escudier, B., Lassau, N., Angevin, E., Soria, J.C., Chami, L., Lamuraglia, M. et al. (2007 b) Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13: 1801-1809.
19. Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C. et al. (2008) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111.
20. Escudier, B., Szczylik, C., Hutson, T.E., Demkow, T., Staehler, M., Rolland, F. et al. (2009) Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 27: 2305.
21. Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N. et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU 11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35.
22. Ferrara, N., Gerber, H.P. and LeCouter, J. (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
23. Figlin, R.A., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Négrier, S. et al. (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26: 5024.
24. Fischer, P., Patel, P., Carducci, M.A., McDermott, D.F., Hudes, G.R., Lubiniecki, G.M. et al. (2008) Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 26: 16020.
25. Flanigan, R.C., Mickisch, G., Sylvester, R., Tangen, C., van Poppel, H. and Crawford, E.D. (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071-1076.
26. Flanigan, R.C., Salmon, S.E., Blumenstein, B.A., Bearman, S.I., Roy, V., McGrath, P.C. et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655-1659.
27. Folkman, J. (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409-416.
28. Garcia, J.A. and Danielpour, D. (2008) Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7: 1347-1354.
29. Gollob, J.A., Rathmell, W.K., Richmond, T.M., Marino, C.B., Miller, E.K., Grigson, G. et al. (2007) Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25: 3288-3295.
30. Golshayan, A.R., George, S., Heng, D.Y., Elson, P., Wood, L.S., Mekhail, T.M. et al. (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 27: 235-241.
31. Hainsworth, J.D., Sosman, J.A., Spigel, D.R., Edwards, D.L., Baughman, C. and Greco, A. (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23: 7889-7896.
32. Hara, S., Oya, M., Mizuno, R., Horiguchi, A., Marumo, K. and Murai, M. (2005) Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16: 928-933.
33. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A. et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
34. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
35. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. and Thun, M.J. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
36. Jermann, M., Stahel, R.A., Salzberg, M., Cerny, T., Joerger, M., Gillessen, S. et al. (2006) A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57: 533-539.
37. Kaelin Jr, W.G. (2007) The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13: 680s-684s.
38. Kondagunta, G.V., Hudes, G.R., Figlin, R., Wilding, G., Hariharan, S., Kempin, S.N. et al. (2007) Motzer sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): results of a dose-finding study. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25: 5101.
39. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F. et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
40. Merchan, J.R., Liu, G., Fitch, T., Picus, J., Qin, R., Pitot, H.C. et al. (2007) Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25: 5034.
41. Messing, E.M., Manola, J., Wilding, G., Propert, K., Fleischmann, J., Crawford, E.D. et al. (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214-1222.
42. Mickisch, G.H., Garin, A., van Poppel, H., de Prijck, L. and Sylvester, R. (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966-970.
43. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A. et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676.
44. Mizukami, Y., Kohgo, Y. and Chung, D.C. (2007) Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 13: 5670-5674.
45. Motzer, R.J., Bacik, J., Schwartz, L.H., Reuter, V., Russo, P., Marion, S. et al. (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454-463.
46. Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S. et al. (2008 b) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
47. Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S. et al. (2008 c) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
48. Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S. et al. (2008 a) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
49. Motzer, R.J., Hudes, G.R., Curti, B.D., McDermott, D.F., Escudier, B.J., Negrier, S. et al. (2007 a) Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25: 3958-3964.
50. Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O. et al. (2007 b) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
51. Motzer, R.J., Michaelson, M.D., Redman, B.G., Hudes, G.R., Wilding, G., Figlin, R.A. et al. (2006 a) Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24.
52. Motzer, R.J., Rini, B.I., Bukowski, R.M., Curti, B.D., George, D.J., Hudes, G.R. et al. (2006 b) Sunitinib in patients with metastatic renal cell carcinoma. Jama 295: 2516-2524.
53. Mrc Re 01 (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353: 14-17.
54. Nagy, A., Balint, I. and Kovacs, G. (2003) Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. Int J Cancer 106: 980-981.
55. Negrier, S., Perol, D., Ravaud, A., Chevreau, C., Bay, J.O., Delva, R. et al. (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110: 2468-2477.
56. O'Farrell, A.M., Foran, J.M., Fiedler, W., Serve, H., Paquette, R.L., Cooper, M.A. et al. (2003) An innovative phase I clinical study demonstrates inhibition of FLT 3 phosphorylation by SU 11248 in acute myeloid leukemia patients. Clin Cancer Res 9: 5465-5476.
57. Oliver, R.T., Nethersell, A.B. and Bottomley, J.M. (1989) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 63: 128-131.
58. Parton, M., Gore, M. and Eisen, T. (2006) Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24: 5584-5592.
59. Patnaik, A., Ricart, A., Cooper, J., Papadopoulos, K., Beeram, M., Mita, C. et al. (2007) A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25: 3512.
60. Pizzocaro, G., Piva, L., Colavita, M., Ferri, S., Artusi, R., Boracchi, P. et al. (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19: 425-431.
61. Prenen, H., Cools, J., Mentens, N., Folens, C., Sciot, R., Schoffski, P. et al. (2006) Efficacy of the kinase inhibitor SU 11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12: 2622-2627.
62. Ratain, M.J., Eisen, T., Stadler, W.M., Flaherty, K.T., Kaye, S.B., Rosner, G.L. et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512.
63. Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Ou, S.S. et al. (2008 b) Bevacizumab plus interferon alfa compared with interferon alfa mono-therapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26: 5422-5428.
64. Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Ou, S.S. et al. (2008 a) Bevacizumab plus interferon alfa compared with interferon alfa mono-therapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26: 5422-5428.
65. Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Ou, S.S. et al. (2008 c) Bevacizumab plus interferon alfa compared with interferon alfa mono-therapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26: 5422-5428.
66. Rini, B.I., Michaelson, M.D., Rosenberg, J.E., Bukowski, R.M., Sosman, J.A., Stadler, W.M. et al. (2008 d) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26: 3743-3748.
67. Rini, B.I., Wilding, G.T., Hudes, G., Stadler, W.M., Kim, S., Tarazi, J.C. et al. (2007) Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25: 5032.
68. Rixe, O., Bukowski, R.M., Michaelson, M.D., Wilding, G., Hudes, G.R., Bolte, O. et al. (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8: 975-984.
69. Rosenberg, S.A., Yang, J.C., White, D.E. and Steinberg, S.M. (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228: 307-319.
70. Rosenberg, J.E., Motzer, R.J., Michaelson, M.D., Redman, B.G., Hudes, G.R., Bukowski, R.M. et al. (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228: 307-319.
71. Rosner, G.L., Stadler, W. and Ratain, M.J. (2002) Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20: 4478-4484.
72. Ryan, C.W., Goldman, B.H., Lara Jr, P.N., Mack, P.C., Beer, T.M., Tangen, C.M. et al. (2007) Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25: 3296-3301.
73. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A. et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
74. Schmidinger, M., Vogl, U.M., Lamm, W., Bojic, M., Bojic, A. and Zielinski, C.C. (2008) Temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma: preliminary results from the Austrian Compassionate Use Programme. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 26: 16125.
75. Stadler, W.M., Rosner, G., Small, E., Hollis, D., Rini, B., Zaentz, S.D. et al. (2005) Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901. J Clin Oncol 23: 3726-3732.
76. Szczylik, C., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Hutson, T.E. et al. (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25: 5025.
77. Tamaskar, I., Garcia, J.A., Elson, P., Wood, L., Mekhail, T., Dreicer, R. et al. (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179: 81-86.
78. Tammela, T., Zarkada, G., Wallgard, E., Murtomaki, A., Suchting, S., Wirzenius, M. et al. (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454: 656-660.
79. Thomas, A.A., Rini, B.I., Lane, B.R., Garcia, J., Dreicer, R., Klein, E.A. et al. (2009) Response of the Primary Tumor to Neoadjuvant Sunitinib in Patients With Advanced Renal Cell Carcinoma. J Urol 181: 518-523.
80. Uhlman, D.L., Nguyen, P., Manivel, J.C., Zhang, G., Hagen, K., Fraley, E. et al. (1995) Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1: 913-920.
81. Weinberg, R.A.( 2007) The Biology of Cancer, Garland Science : New York.
82. Whorf, R.C., Hainsworth, J.D., Spigel, D.R., Yardley, D.A., Burris III, H.A., Waterhouse, D.M. et al. (2008) Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 26: 5010.
83. Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
84. Witzig, T.E., Geyer, S.M., Ghobrial, I., Inwards, D.J., Fonseca, R., Kurtin, P. et al. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23: 5347-5356.
85. Yagoda, A. and Bander, N.H. (1989) Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 44: 338-345.
86. Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L. et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434.